Anton Birn, CEO, DemensAI

The diagnostic pathway for a dementia diagnosis is rapidly growing with the elder burden. Currently, some places in Denmark experience waiting times of upwards to 1 year from first GP visit to final diagnosis. With new drugs entering the market, which can postpone cognitive decline, it is paramount to get an early diagnosis.

The talk will be presenting our study, which implemented a machine learning model to classify between healthy control and Alzheimer's Disease patients based on 1 minute speech samples. Furthermore, it will explain where this technology could take cognitive screenings in terms of precision, timing, scalability, availability and cost.

DemensAI is a pioneering startup aiming to revolutionize dementia diagnosis through cutting-edge artificial intelligence. Founded by Anton Boldrup Birn, Laurine Dargaud, and Abhista Partal, DemensAI's innovative AI technology utilizes speech recognition and language analysis to assess cognitive function swiftly and accurately. 

By providing a non-invasive, digital solution, DemensAI aims to facilitate early detection of Alzheimer's and other forms of dementia, ultimately paving the way for timely intervention and improved patient outcomes. 

Their vision is to empower healthcare professionals with a tool that can efficiently screen individuals for dementia, leading to earlier diagnoses and potentially enhancing the efficacy of emerging treatments like Lecanemab and Donanemab.

This is from the conference "Artificial Intelligence in Healthcare".

Join the discussion about the future of healthcare at our conference, where AI's power to transform patient care through swift, accurate data processing and task automation takes center stage.